[{"arm_notes": "", "treatment_id": null, "treatment_name": "Once enrolled; they are assigned to the treatment arms by randomisation. Study participants will then be assigned to one of two arms in a 1:1 ratio - the tasquinimod (experimental) arm and the placebo (control) arm. Tasquinimod is the major 2nd generation quinoline-3-carboxamide; which is orally active and was being developed for prostate cancer. It will be administered in its capsule formulation; and has a half-life of 40\u00b116 hours; with maximum serum concentration seen within 2.6 hours. Study participants will be given an initial dose of 0.5mg daily for the 1st fortnight and then dose increased to 1mg daily for the 2nd fortnight of the 28-day study period. If a study participant misses a dose of tasquinimod; the next dose should be given as already planned. If a study participant misses two or more doses of tasquinimod; then the Principal Investigator (PI) should be alerted ASAP.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 1264, "treatment_name": "Tasquinimod", "treatment_type": "Others pharmacological treatment", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]